Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Moodys
Boehringer Ingelheim
McKinsey
Colorcon

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Resminostat

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Resminostat: Sponsors, patents, clinical trial progress

Resminostat is an investigational drug.

There have been 5 clinical trials for Resminostat. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Hepatocellular, and Mycoses. The leading clinical trial sponsors are 4SC AG, Yakult Honsha Co., LTD, and [disabled in preview].

There are nine US patents protecting this investigational drug and one hundred and twenty-three international patents.

Recent Clinical Trials for Resminostat
TitleSponsorPhase
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or S├ęzary Syndrome (SS)4SC AGPhase 2
Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)Yakult Honsha Co., LTDPhase 1/Phase 2
4SC-201 (Resminostat) in Advanced Colorectal Carcinoma4SC AGPhase 1/Phase 2

See all Resminostat clinical trials

Clinical Trial Summary for Resminostat

Top disease conditions for Resminostat
Top clinical trial sponsors for Resminostat

See all Resminostat clinical trials

US Patents for Resminostat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Resminostat   Start Trial Sulfonylpyrroles 4SC AG (Planegg Martinsrid, DE)   Start Trial
Resminostat   Start Trial Sulphonylpyrroles 4SC AG (Planegg Martinsrid, DE)   Start Trial
Resminostat   Start Trial Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors 4SC AG (Planegg Martinsrid, DE)   Start Trial
Resminostat   Start Trial Sulphonylpyrroles as inhibitors of HDACs novel sulphonylpyrroles 4SC AG (Planegg Martinsrid, DE)   Start Trial
Resminostat   Start Trial Sulfonylpyrroles 4SC AG (Planegg Martinsrid, DE)   Start Trial
Resminostat   Start Trial Sulfonylpyrroles 4SC AG (Planegg-Martinsreid, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Resminostat

Drugname Country Document Number Estimated Expiration Related US Patent
Resminostat Argentina 048427 2024-03-11   Start Trial
Resminostat Australia 2005221834 2024-03-11   Start Trial
Resminostat Brazil PI0508464 2024-03-11   Start Trial
Resminostat Canada 2558552 2024-03-11   Start Trial
Resminostat China 1926103 2024-03-11   Start Trial
Resminostat Cyprus 1114284 2024-03-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Merck
Moodys
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.